Catalytic antibodies and their applications in biotechnology: State of the art

Biotechnology Letters

Volumn 36, Issue 7, 2014, Pages 1369-1379

  Padiolleau Lefèvre, Séverine ^a   Naya, Raouia Ben ^a   Shahsavarian, Melody A ^a   Friboulet, Alain ^a   Avalle, Bérangère ^a  

^a UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

Abzymes; Catalytic antibodies; Cocaine; Immunoglobulin; Phage display (for abzymes); Prodrug therapy (abzymes)

Indexed keywords

BIOTECHNOLOGY;

ABZYMES; CATALYTIC ANTIBODIES; COCAINE; IMMUNOGLOBULIN; PHAGE DISPLAY; PRODRUGS;

ANTIBODIES;

CATALYTIC ANTIBODY;

BIOTECHNOLOGY; CELL SURFACE DISPLAY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES;

ANTIBODIES, CATALYTIC; BIOTECHNOLOGY; CELL SURFACE DISPLAY TECHNIQUES;

EID: 84902287617     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-014-1503-8     Document Type: Review

References (61)

1. Ali M, Suzuki H, Fukuba T, Jiang X, Nakano H, Yamane T (2005) Improvements in the cell-free production of functional antibodies using cell extract from protease-deficient Escherichia coli. J Biosci Bioeng 99: 181-186.
2. Avalle B, Thomas D, Friboulet A (1998) Functional mimicry: elicitation of a monoclonal anti-idiotypic antibody hydrolysing β-lactams. FASEB J 12: 1055-1060.
3. Ben Naya R, Matti K, Guellier A, Matagne A, Boquet D, Thomas D, Friboulet A, Avalle B, Padiolleau-Lefèvre S (2013) Efficient refolding of a recombinant abzyme: structural and catalytic characterizations. Appl Microbiol Biotechnol 97: 7721-7731.
4. Berkmen M (2012) Production of disulfide-bonded proteins in Escherichia coli. Prot Expr Purif 82: 240-251.
5. Bowdish K, Tang Y, Hicks JB, Hilvert D (1991) Yeast expression of a catalytic antibody with chorismate mutase activity. J Biol Chem 18: 11901-11908.
6. Briscoe RJ, Jeanville PM, Cabrera C, Baird TJ, Woods JH, Landry DW (2001) A catalytic antibody against cocaïne attenuates cocaine's cardiovascular effects in mice: a dose and time course analysis. Int Immunopharmacol 1: 1189-1198.
7. Cai X, Whitfield T, Hixon MS, Grant Y, Koob GF, Janda KD (2013) Probing active cocaïne vaccination performance through catalytic and noncatalytic hapten design. J Med Chem 56: 3701-3709.
8. Deng SX, de Prada P, Landry DW (2002) Anticocaine catalytic antibodies. J Immunol Methods 269: 299-310.
9. Dickerson TJ, Yamamoto N, Janda KD (2004) Antibody-catalytzed oxidative dégradation of nicotine using riboflavin. Bioorg Med Chem 12: 4981-4987.
10. Gibbs RA, Posner BA, Filpula DR, Dodd SW, Finkelman MAJ, Lee TK, Wroble M, Whitlow M, Benkovic SJ (1991) Construction and characterization of a single-chain catalytic antibody. Proc Natl Acad Sci USA 88: 4001-4004.
11. Gonçalves O, Dintinger T, Blanchard D, Tellier C (2002) Functional mimicry between anti-tendamistat antibodies and α-amylase. J Immunol Methods 269: 29-37.
12. Gorelick DA (2012) Pharmacokinetic strategies for treatment of drug overdose and addiction. Future Med Chem 4: 227-243.
13. Goswami RK, Huang ZZ, Forsyth JS, Felding-Habermann B, Sinha SC (2009) Multiple catalytic aldolase antibodies suitable for chemical programming. Bioorg Med Chem Lett 19: 3821-3824.
14. Hifumi E, Morihara F, Hatiuchi K, Okuda T, Nishizono A, Uda T (2008) Catalytic features and eradication ability of antibody light chain UA15-L against H. pylori. J Biol Chem 283: 899-907.
15. Hifumi E, Higashi K, Uda T (2010) Catalytic digestion of human tumor necrosis factor-α by antibody heavy chain. FEBS J 277: 3823-3832.
16. Hifumi E, Honjo E, Fujimoto N, Arakawa M, Nishizono A, Uda T (2013) Highly efficient method of preparing human catalytic antibody light chains and their biological characteristics. FASEB J 26: 1607-1615.
17. Hilvert D, Carpenter SH, Nared KD, Auditor MT (1988) Catalysis of concerted reactions by antibodies: the Claisen rearrangement. Proc Natl Acad Sci USA 85: 4953-4955.
18. Hu R, Xie GY, Zhang X, Guo ZQ, Jin S (1998) Production and characterization of monoclonal anti-idiotypic antibody exhibiting a catalytic activity similar to carboxypeptidase. J Biotechnol 61: 109-115.
19. Izadyar L, Friboulet A, Remy MH, Roseto A, Thomas D (1993) Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc Natl Acad Sci USA 90: 8876-8880.
20. Janda KD, Weinhouse MI, Schloeder DM, Lerner RA, Benkovic SJ (1990) Bait and switch strategy for obtaining catalytic antibodies with acyl-transfer capabilities. J Am Chem Soc 112: 1274-1275.
21. Jang C, Machtaler S, Matsuuchi L (2010) The role of Ig-α/β in B cell antigen receptor internalization. Immunol Lett 134: 75-82.
22. Jencks WP (1969) Catalysis in chemistry and enzymology. Mc-Graw-Hill Book Co. Inc., New York.
23. Jerne NK (1974) Towards a network theory of the immune system. Annu Immunol (Paris). 125C: 373-389.
24. Jiang XP, Ookubo Y, Fujii I, Nakano H, Yamane T (2002) Expression of Fab fragment of catalytic antibody 6D9 in an Escherichia coli in vitro coupled transcription/translation system. FEBS Lett 514: 290-294.
25. Kim SH, Schindler DG, Lindner AB, Tawfik DS, Eshhar Z (1997) Expression and characterization of recombinant single-chain Fv and Fv fragments derived from a set of catalytic antibodies. Mol Immunol 34: 891-906.
26. Kohler G, Milstein C (1975) Continuous culture of fused cells secreting antibody or predefined specificity. Nature 256: 495-497.
27. Kozyr AV, Bobik TV, Ignatova AN, Kolesnikov AV (2004) Production of DNA-hydrolyzing antibody BV04-01 Fab fragment in methylotrophic yeast Pichia pastoris. Mol Biol 38: 914-920.
28. Kurkova IN, Reshetnyak AV, Durova OM, Knorre VD, Tramontano A, Friboulet A, Ponomarenko NA, Gabibov AG, Smirnov IV (2009) Antibodies-antidotes against organophosphorus compounds. Dokl Akad Nauk 425: 549-552.
29. Lee WR, Jang JY, Kwon MH, Kim YS (2010) Gene silencing by cell-penetrating, sequence-selective and nucleic-acid hydrolyzing antibodies. Nucleic Acids Res 38: 1596-1609.
30. Li JW, Xia L, Su Y, Liu H, Xia X, Lu Q, Yand C, Reheman K (2012) Molecular imprint of enzyme active site by camel nanobodies: rapid and efficient approach to produce abzyme with aliinase activity. J Biol Chem 287: 13713-13721.
31. McKenzie KM, Mee JM, Rogers CJ, Hixon MS, Kaufmann GF, Janda KD (2007) Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol 365: 722-731.
32. Padiolleau-Lefèvre S, Débat H, Phichith D, Thomas D, Friboulet A, Avalle B (2006) Expression of a functional scFv fragment of an anti-idiotypic antibody with a β-lactam hydrolytic activity. Immunol Lett 103: 39-44.
33. Paul S, Planque S, Zhou XY, Taguchi H, Bathia G, Karle S, Hanson C, Nishiyama Y (2003) Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem 278: 20429-20435.
34. Paul S, Planque S, Nishiyama Y (2010) Immunological origin and functional properties of catalytic autoantibodies to amyloid β peptide. J Clin Immunol 30: S43-S49.
35. Pauling L (1948) Chemical achievement and hope for the future. Am Sci 36: 51-58.
36. Phichith D, Bun S, Padiolleau-Lefèvre S, Banh S, Thomas D, Friboulet A, Avalle B (2009) Mutational and inhibitory analysis of a catalytic antibody. Implication for drug discovery. Mol Immunol 47: 348-356.
37. Pillet D, Paon M, Vorobiev II, Gabibov AG, Thomas D, Friboulet A (2002) Idiotypic network mimicry and antibody catalysis: lessons for the elicitation of efficient anti-idiotypic protease antibodies. J Immunol Methods 269: 5-12.
38. Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S (2008) Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev 7: 473-479.
39. Pollack SJ, Jacobs JW, Schultz PG (1986) Selective chemical catalysis by an antibody. Science 234: 1570-1573.
40. Ponomarenko NA, Pillet D, Paon M, Vorobiev II, Smirnov IV, Adenier H, Avalle B, Kolesnikov AV, Kozyr A, Thomas D, Gabibov AG, Friboulet A (2007) Anti-idiotypic antibody mimics proteolytic function of parent antigen. Biochemistry 46: 14598-14609.
41. Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR (2003) Degradation of β-amyloid by proteolytic antibody light chains. Biochemistry 42: 14328-14334.
42. Rao D, Wootla B (2007) Catalytic antibodies: concept and promise. Resonance (Springerlink) 12: 6-21.
43. Reshetnyak AV, Armentano MF, Ponomarenko NA, Vizzuso D, Durova OM, Ziganshin R, Serebryakova M, Govorun V, Gololobov G, Morse HC, Friboulet A, Makker SP, Gabibov AG, Tramontano A (2007) Routes to covalent catalysis by reactive selection for nascent protein nucleophiles. J Am Chem Soc 129: 16175-16182.
44. Robin S, Petrov K, Dintinger T, Kujumdzieva A, Tellier C, Dion M (2003) Comparison of three microbial hosts for the expression of an active catalytic scFv. Mol Immunol 39: 729-738.
45. Shamis M, Lode HN, Shabat D (2004) Bioactive of self-immolative dendritic prodrugs by catalytic antibody 38C2. J Am Chem Soc 126: 1726-1731.
46. Sinha SC, Li LS, Miller GP, Dutta S, Rader C, Lerner RA (2004) Prodrugs of dynemicin analogs for selective chemotherapy mediated by an alodolase catalytic Ab. Proc Natl Acad Sci USA 101: 3095-3099.
47. Smirnov I, Carletti E, Kurkova I, Nachon F, Nicolet Y, Mitkevich VA, Débat H, Avalle B, Belogurov AA, Kuznetsov N, Reshetnyak A, Masson P, Tonevitsky AG, Ponomarenko N, Makarov AA, Friboulet A, Tramontano A, Gabibov A (2011) Reactibodies generated by kinetic selection couple chemical reactivity with favorable protein dynamics. Proc Natl Acad Sci USA 108: 15954-15959.
48. Stewart JD, Benkovic SJ (1995) Transition-state stabilization as a measure of the efficiency of antibody catalysis. Nature 375: 388-391.
49. Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Sudhir P (2008) Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease. Autoimmun Rev 7: 391-397.
50. Takahashi N, Kakinuma H, Liu L, Nishi Y, Fujii I (2001) In vitro abzyme evolution to optimize antibody recognition for catalysis. Nat Biotechnol 19: 563-567.
51. Takahashi-Ando N, Kakinuma H, Fujii I, Nishi Y (2004) Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analog. J Immunol Methods 294: 1-14.
52. Tramontano A, Janda KD, Lerner R (1986) Chemical reactivity at an antibody binding site elicited by mechanistic design of a synthetic antigen. Proc Natl Acad Sci USA 89: 7114-7118.
53. Treweek JB, Janda KD (2012) An antidote for acute cocaine toxicity. Mol Pharm 9: 969-978.
54. Wirsching P, Ashley JA, Lo CHL, Janda KD, Lerner RA (1995) Reactive immunization. Science 270: 1775-1782.
55. Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repressé Y, Ollivier V, Friboulet A, Borel-Delon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S (2011a) Proteolytic antibodies activate factor IX in patients with acquired haemophilia. Blood 117: 2257-2264.
56. Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri S, Rodriguez M (2011b) Autoantibodies with enzymatic properties in human autoimmune diseases. J Autoimmun 37: 144-150.
57. Wörn A, Plückthun A (2001) Stability engineering of antibody single-chain Fv fragments. J Mol Biol 305: 989-1010.
58. Xu Y, Yamamoto N, Janda K (2004) Catalytic antibodies: hapten design strategies and screening methods. Bioorg Med Chem 12: 5247-5268.
59. Xu J, Song J, Su J, Wei J, Yu Y, Lv S, Li W, Nie G (2010) A new human catalytic antibody Se-scFv-2D8 and its selenium-containing single domains with high GPX activity. J Mol Recognit 23: 352-359.
60. Yin J, Li G, Ren X, Herrler G (2007) Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol 127: 335-347.
61. Zakharov AV, Smirnov IV, Serebryakova MV, Dronina MA, Kaznacheeva AV, Kurkova IN, Belogurov AA, Friboulet A, Ponomarenko NA, Gabibov AG, Bobik TV (2011) Expression of catalytic antibodies in eukaryotic systems. Mol Biol 45: 86-95.